Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Planning To Leverage Biosimilar Cost Competitiveness After Filings In Korea And US
• By David Wallace
Celltrion is planning to leverage its cost competitiveness on bevacizumab • Source: Alamy 
